Journal of International Oncology››2014,Vol. 41››Issue (5): 386-389.doi:10.3760/cma.j.issn.1673-422X.2014.05.020
Previous ArticlesNext Articles
Xu Huaping, Wei Lingxia, Dong Yanlei, Zhang Shiqian
Received:
2013-10-14Revised:
2014-01-10Online:
2014-05-08Published:
2014-04-28Contact:
Zhang Shiqian E-mail:zhangshiqian370112@126.comXu Huaping, Wei Lingxia, Dong Yanlei, Zhang Shiqian. Effects of 5-aza-2′deoxycitydine on expression of RASSF1A gene in human ovarian cancer cell line[J]. Journal of International Oncology, 2014, 41(5): 386-389.
[1] Ahmed N, Abubaker K, Findlay J, et al. Epithelial mesenchymal transition and cancer stem celllike phenotypes facilitate chemoresistance in recurrent ovarian cancer[J]. Curr Cancer Drug Targets, 2010, 10(3):268-278. [2] Hope JM, Blank SV. Current status of maintenance therapy for advanced ovarian cancer[J]. Int J Women′s Health, 2010, 1:173-180. [3] Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization[J]. Biochim Biophys Acta, 2009, 1796(2):114-128. [4] Oceandy D, Cartwright EJ, Neyses L. Rasassociation domain family member 1A (RASSF1A)where the heart and cancer meet[J]. Trends Cardiovasc Med, 2009, 19(8):262-267. [5] Fukushige S, Horii A. DNA methylation in cancer: agene silencing mechanism and the clinical potential of its biomarkers[J]. Tohoku J Exp Med, 2013, 229(3):173-185. [6] Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization[J]. Biochim Biophys Acta, 2009, 1796(2):114-128. [7] Wang YC, Yu ZH, Chen LB. Role of RASSF1A hypermethylation in prostate cancer[J]. Zhonghua Nan Ke Xue, 2007, 13(9):822-825. [8] Hu L, Chen G, Yu H, et al. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(1):423-432. [9] Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours[J]. Oncogene, 2001, 20(12):1509-1518. [10] Chaudhry P, Srinivasan R, Patel FD. Utility of gene promoter methylation in prediction of response to platinumbased chemotherapy in epithelial ovarian cancer (EOC)[J]. Cancer Invest, 2009, 27(8):877-884. [11] Lindner DJ, Wu Y, Haney R, et al. Thrombspondin1 expression in melanoma is blocked by methyltion and targeted reversal by 5Azadeoxycytidine suppresses angiogenesis[J]. Matrix Biol, 2013, 32(2):123-132. [12] Cataldo VD, Cortes J, QuintásCardama A. Azacitidine for the treatment of myelodysplastic syndrome[J]. Expert Rev Anticancer Ther, 2009, 9(7):875-884. |
[1] | Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190. |
[2] | An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497. |
[3] | Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347. |
[4] | Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226. |
[5] | Li Chenxi, Zhao Hongwei.Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183. |
[6] | Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao.GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway[J]. Journal of International Oncology, 2021, 48(12): 716-722. |
[7] | Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan.Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer[J]. Journal of International Oncology, 2021, 48(11): 660-665. |
[8] | Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran.Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells[J]. Journal of International Oncology, 2020, 47(6): 333-339. |
[9] | Xue Chen, Zhao Yue, Shi Guang, Tang Yan.Research progress of PD-1/PD-L1 inhibitors in ovarian cancer[J]. Journal of International Oncology, 2020, 47(5): 312-315. |
[10] | Yang Yiting, Cheng Zhongping.The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer[J]. Journal of International Oncology, 2020, 47(4): 249-251. |
[11] | Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan.Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance[J]. Journal of International Oncology, 2020, 47(2): 82-89. |
[12] | Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian.Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels[J]. Journal of International Oncology, 2020, 47(10): 606-610. |
[13] | Tang Nanmin, Yu Zhancai.Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer[J]. Journal of International Oncology, 2019, 46(9): 562-565. |
[14] | Chu Chaonan, Huang Qi.Comparison of the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum resistant ovarian cancer[J]. Journal of International Oncology, 2019, 46(1): 32-35. |
[15] | Yuan Qiuyue, Qiao Huimin, Zhang Shengmiao, Xia Baoguo, Bi Shuna, Chen Long.Research progress of circulating tumor DNA in ovrian cancer[J]. Journal of International Oncology, 2019, 46(1): 57-60. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||